Atorvastatin Overcomes Gefitinib Resistance in KRAS Mutant Human Non-Small Cell Lung Carcinoma Cells

Cell Death and Disease - United Kingdom
doi 10.1038/cddis.2013.312
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Author Correction: Targeting Hsp90 With FS-108 Circumvents Gefitinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells

Acta Pharmacologica Sinica
MedicinePharmacology
2020English

Silibinin Reverses Drug Resistance in Human Small-Cell Lung Carcinoma Cells

Cancer Letters
Cancer ResearchOncology
2013English

Synthetic Lethal Therapy for KRAS Mutant Non-Small-Cell Lung Carcinoma With Nanoparticle-Mediated CDK4 siRNA Delivery

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Role of FBXW7 in the Quiescence of Gefitinib-Resistant Lung Cancer Stem Cells in EGFR-mutant Non-Small Cell Lung Cancer

Bosnian Journal of Basic Medical Sciences
Medicine
2019English

Gefitinib-Induced Intestinal Obstruction in Advanced Non-Small Cell Lung Carcinoma: A Case Report

Oncology Letters
Cancer ResearchOncology
2015English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

Overexpression of OCT4 Is Associated With Gefitinib Resistance in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy